Gastric Antisecretory Drug Market Report 2026

The gastric antisecretory drug market size has grown strongly in recent years. It will grow from $15.63 billion in 2025 to $16.53 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to high prevalence of acid-related disorders, increased diagnosis of gastroesophageal reflux disease, expansion of hospital pharmacies, widespread use of h2 receptor antagonists, growth in self-medication trends.

The gastric antisecretory drug market size is expected to see strong growth in the next few years. It will grow to $20.7 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to aging population growth, rising stress-related gastric disorders, expansion of otc drug markets, increased healthcare awareness, development of safer long-term therapies. Major trends in the forecast period include increasing use of proton pump inhibitors, rising demand for long-term acid suppression, growing preference for oral drug formulations, expansion of over-the-counter availability, increasing focus on gastrointestinal disease management.

The prevalence of gastrointestinal disorders is anticipated to drive the growth of the gastric antisecretory drug market in the coming years. Gastrointestinal disorders affect the digestive tract, including the stomach, intestines, and associated organs, causing symptoms such as pain, bloating, and altered bowel movements. The increase in gastrointestinal disorders is mainly driven by poor dietary habits, as excessive consumption of processed foods and inadequate fiber intake lead to imbalances in gut microbiota and impaired digestion. Gastric antisecretory drugs are essential because excessive stomach acid can damage the protective lining of the gastrointestinal tract, resulting in irritation or injury, which these drugs help prevent by reducing acid production. For instance, in June 2025, according to the Turkish Journal of Gastroenterology, a Turkey-based journal, around 6.9 million individuals globally are currently suffering from inflammatory bowel disease (IBD). Therefore, the rising prevalence of gastrointestinal disorders will boost the growth of the gastric antisecretory drug market.

Major companies operating in the gastric antisecretory drug market are concentrating on developing advanced products, such as antisecretory compounds, to deliver longer-lasting relief. Antisecretory compounds are agents that reduce or inhibit the secretion of bodily fluids, particularly gastric acid, by acting on specific cellular pathways or receptors. For instance, in June 2024, Akums Drugs and Pharmaceuticals, an India-based pharmaceutical company, launched Rabeprazole + Levosulpiride SR Capsules, a novel formulation for gastrointestinal patients. This formulation combines rabeprazole sodium, a strong antisecretory agent that selectively inhibits the H⁺/K⁺ ATPase in gastric parietal cells, with levosulpiride, which has central antidopaminergic and antiemetic properties. The capsule contains 40 mg of enteric-coated rabeprazole and 75 mg of sustained-release levosulpiride, ensuring targeted and prolonged therapeutic action. Its dual mechanism supports both acid suppression and regulation of gastrointestinal motility.

In July 2024, Merit Medical Systems, Inc., a US-based developer and manufacturer of disposable medical devices for interventional and diagnostic procedures, acquired the EsophyX Z+ device and related assets from EndoGastric Solutions, Inc. for approximately $105 million. Through this acquisition, Merit seeks to enhance its gastrointestinal and endoscopy portfolio by incorporating a durable, minimally invasive, non-pharmacological treatment option for gastroesophageal reflux disease (GERD), thereby complementing existing drug-based acid suppression therapies. EndoGastric Solutions, Inc. is a US-based company that develops the EsophyX Z+ system for transoral incisionless fundoplication.

Major companies operating in the gastric antisecretory drug market are Pfizer Inc., Bayer AG, AstraZeneca plc, Takeda Pharmaceutical Company Ltd., Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Chemo Biological, Spansules Pharmatech Pvt. Ltd., Phoenix Biologicals Pvt. Ltd., Centurion Remedies Private Limited, Solitaire Pharmacia Pvt. Ltd., Shreeji Pharma International, Estrellas Life Sciences Private Limited, 3s Corporation, Actiza Pharmaceutical Private Limited, Lark Laboratories, Cytonova Labs International Private Limited, Luckys Pharma Lab Pvt. Ltd., Lexicare Pharma Pvt. Ltd., Mustcure Healthcare LLP.

North America was the largest region in the gastric antisecretory drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric antisecretory drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric antisecretory drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the gastric antisecretory drug market by increasing the cost of imported active pharmaceutical ingredients and excipients used in acid-suppressing medications. These impacts have been most pronounced in proton pump inhibitor segments across North America and Europe. Asia-Pacific manufacturers have faced supply chain disruptions due to api sourcing dependencies. However, tariffs have encouraged local api production and generic drug manufacturing, supporting supply continuity.

The gastric antisecretory drug market research report is one of a series of new reports that provides gastric antisecretory drug market statistics, including gastric antisecretory drug industry global market size, regional shares, competitors with a gastric antisecretory drug market share, detailed gastric antisecretory drug market segments, market trends and opportunities, and any further data you may need to thrive in the gastric antisecretory drug industry. This gastric antisecretory drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A gastric antisecretory drug is a medication used to reduce the production of gastric acid in the stomach. These drugs act by inhibiting specific pathways or receptors involved in acid secretion, thereby lowering the acidity of stomach contents. By helping maintain a more neutral gastric pH, gastric antisecretory drugs protect the stomach lining and support digestive balance.

The main classes of gastric antisecretory drugs include proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, and prostaglandin analogs. PPIs are medications that decrease stomach acid production by irreversibly blocking the H⁺/K⁺-ATPase enzyme in gastric parietal cells. They can be administered through oral, intravenous, or topical routes and are distributed via hospital pharmacies, retail pharmacies, online pharmacies, and other channels. These drugs are used to treat conditions such as gastroesophageal reflux disease, peptic ulcer disease, Zollinger-Ellison syndrome, and others.

The gastric antisecretory drug market consists of sales of mucosal protective agents, digestive enzyme supplements, probiotics for gut health, and controlled-release formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.